NCT04428008View on ClinicalTrials.gov

Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

262

Participants

Timeline

Start Date

January 12, 2021

Primary Completion Date

January 19, 2023

Study Completion Date

January 19, 2023

Conditions

COVID-19

Interventions

DRUG

Thymalfasin

Synthetic 28 amino acid peptide

Trial Locations (1)

64111

Clinical Research Consultants, Kansas City

Sponsors

Collaborators (1)

Davita Clinical Research

All Listed Sponsors

collaborator

Davita Clinical Research

INDUSTRY

collaborator

Ahmed Awad, MD

UNKNOWN

lead

William B. Ershler, MD

OTHER

NCT04428008 - Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients | Biotech Hunter | Biotech Hunter